etoposide has been researched along with belotecan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hwang, JH; Kang, S; Lim, MC; Park, SY; Seo, SS; Yoo, HJ | 1 |
| Jang, TW; Jeong, JH; Kim, KS; Kim, SY; Kim, YC; Lee, HK; Lee, JE; Lee, KH; Lee, KY; Lee, SY; Oh, IJ; Park, CK; Shin, KC | 1 |
2 trial(s) available for etoposide and belotecan
| Article | Year |
|---|---|
Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Thrombocytopenia; Treatment Outcome | 2012 |
Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2016 |